

**The Walter P. Scheffe Continuing Pharmaceutical Education Series  
October 28-29, 2023 | OU College of Pharmacy | Oklahoma City, OK**

**SYLLABUS**

**October 28, 2023 – 8 contact hours (0.8 CEUs) total**

7:30-7:55am      **Registration & Continental Breakfast**

7:55-8:00am      **Introduction**

8:00-10:00am      **Improving Quality of Care and Outcomes: Applications of  
Pharmacoeconomics and Value-Based Frameworks\* (K)**

ACPE # 0053-0000-23-024-L05-P | 2 contact hours (0.2 CEUs)

*Grant Skrepnek, Ph.D., M.Sc., R.Ph., Professor, OU College of Pharmacy, OKC*

At the completion of this activity, pharmacists will be able to summarize general principals of value, cost-effectiveness analyses, and value-based frameworks and define and quantify the incidence, prevalence, and impact of medical errors, medication errors, drug-related problems, adverse drug events, and adverse drug reactions.

10:00-10:15am      **Break**

10:15-12:15pm      **Managing Major Geriatric Syndromes - Fact, Fiction, Updates and Clinical  
Pearls\* (A)**

ACPE # 0053-0000-23-025-L01-P | 2 contact hours (0.2 CEUs)

*Keith Swanson, Pharm.D., Associate Professor, OU College of Pharmacy, OKC*

At the completion of this activity, pharmacists will be able to compare the pharmacologic activity and potential adverse effects of medications used to manage dementia, predict the potential benefits and risks associated with the use of medications commonly used to treat urinary incontinence, describe the known benefit of medications and nutritional supplements used to reduce the risk of recurrent urinary tract infections, examine the potential benefits and risks associated with therapies for managing the behavioral and psychiatric symptoms of dementia, and summarize the potential benefits and risks associated with medications used to manage weight loss in older individuals.

12:15-12:45pm      **Lunch**

12:45-1:45pm      **Breaking Bad Cholesterol: The Latest Dyslipidemia Management  
Strategies\* (A)**

ACPE # 0053-0000-23-026-L01-P | 1 contact hour (0.1 CEU)

*Jordan Fuller, Pharm.D., M.B.A., BCPS, BCCCP, Assistant Professor, OU College of Pharmacy, OKC*

At the completion of this activity, pharmacists will be able to interpret treatment recommendations included in the 2018 ACC-AHA, 2019 ESC/EAS, and 2020 AACE/ACE hypercholesterolemia guidelines, explain the role of nonstatin therapies for LDL-cholesterol management, and apply guidelines for the management of patients with hypercholesterolemia.

1:45-2:45pm      **USP 795 and 797 Chapter Updates\* (K)**

ACPE # 0053-0000-23-027-L07-P | 1 contact hour (0.1 CEU)

Wendy Galbraith, Pharm.D., FAPhA, BCNP, Clinical Associate Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to report the major changes in USP compounding chapters, classify a sterile preparation given the environmental engineering controls, and identify the appropriate beyond-use date for acquired data.

2:45-3:00pm **Break**

3:00-5:00pm **The Ins and Outs of Ups and Downs: Antidepressant, Neuroleptic, and Lithium Overdoses\* (A)**

ACPE # 0053-0000-23-028-L01-P | 2 contact hours (0.2 CEUs)

Kristie Edelen, Pharm.D., D.A.B.A.T., Managing Director, Oklahoma Poison Center, OKC

At the completion of this activity, pharmacists will be able to describe the mechanisms of toxicity and clinical effects of antidepressant and neuroleptic medications, develop a treatment strategy for a patient suffering from antidepressant and neuroleptic overdose, and choose effective treatment plans for serotonin toxicity and neuroleptic malignant syndrome.

5:00-5:05pm **Closing Remarks & Evaluation**

**October 29, 2023 – 7 contact hours (0.7 CEUs) total**

7:30-7:55am **Registration & Continental Breakfast**

7:55-8:00am **Introduction**

8:00-9:30am **Incretin-Based Therapies: The Past, Present, and Future of Weight Loss Drugs\* (A)**

ACPE # 0053-0000-23-029-L01-P | 1.5 contact hours (0.15 CEUs)

Jeremy Johnson, Pharm.D., BCACP, CDCES, BC-ADM, Associate Professor, SWOSU College of Pharmacy, Tulsa

At the completion of this activity, pharmacists will be able to interpret findings from select trials regarding incretin analogues and weight loss, identify which incretin analogue products are approved for weight loss, and apply evidence of weight loss with incretin analogues to patient case scenarios.

9:30-9:45am **Break**

9:45-10:45am **The Sweet Accessibility of Continuous Glucose Monitors\* (K)**

ACPE # 0053-0000-23-030-L01-P | 1 contact hour (0.1 CEU)

Julia McElyea, Pharm.D., BCACP, Clinical Assistant Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to describe the recent expansion of continuous glucose monitoring (CGM) coverage, recognize the benefits of CGM use compared to traditional glucose monitoring, state the differences of personal CGM devices on the market, and recall recommendations pertaining to the procurement, usage, and interpretation of CGMs.

10:45-11:45am **It Takes Two to Tango: Dual Inhaled Bronchodilators for Chronic Obstructive Pulmonary Disease\* (A)**

ACPE # 0053-0000-23-031-L01-P | 1 contact hour (0.1 CEU)

Paul Boylan, Pharm.D., BCPS, Assistant Professor, OU College of Pharmacy, OKC

At the completion of this activity, pharmacists will be able to report updates to the Global Initiative for Obstructive Lung Disease (GOLD) 2023 Report, explain the pharmacology, medicinal chemistry, and pharmacokinetic properties of long-acting beta agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), and choose long-acting bronchodilators to treat GOLD Categories B and E.

11:45-12:15pm      **Lunch**

12:15-1:45pm      **Oklahoma State Board of Pharmacy Rule Update\* (K)**

ACPE # 0053-0000-23-032-L03-P | 1.5 contact hours (0.15 CEUs)

*Marjan Fardadfar, Pharm.D., D.Ph., BCGP, Compliance Officer, Oklahoma State Board of Pharmacy, OKC*

At the completion of this activity, pharmacists will be able to report recent changes in Oklahoma pharmacy laws and rules and explain how laws and rules apply to pharmacy practices in Oklahoma.

1:45-2:00pm      **Break**

2:00-4:00pm      **This is The Way: Empiric Treatment Updates of Infectious Diseases\* (A)**

ACPE # 0053-0000-23-033-L01-P | 2 contact hours (0.2 CEUs)

*Kelly Murray, Pharm.D., BCACP, Clinical Associate Professor of Clinical Pharmacy, OSU Center for Health Sciences, Tulsa*

At the completion of this activity, pharmacists will be able to list appropriate first- and second-line options for urinary tract infections, choose empiric treatment options for patients diagnosed with community acquired pneumonia based on past medical history, select options for acute bacterial skin and skin structure infections in pregnant or breastfeeding patients, state the current antibiotics and dosages for treatment of gonorrhea, and analyze literature on anaerobic coverage with metronidazole in pelvic inflammatory disease.

4:00-4:05pm      **Closing Remarks & Evaluation**

## **Target Audience**

This continuing education program is intended for pharmacists in any practice setting.

## **Continuing Education**

\*Denotes sessions of Continuing Education credit provided by the University of Oklahoma College of Pharmacy. Please note next to the ACPE # the type of activity: (K) = Knowledge-based & (A) = Application-based. These activities are structured to meet knowledge- and/or application-based education needs. A knowledge-based activity is for participants to acquire factual knowledge. An application-based activity is for participants to apply the information learned in the allotted timeframe. Information in all continuing education activities is based on evidence as accepted in the literature by the healthcare professions.



The University of Oklahoma College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

## **Awarding Credit**

This seminar offers a total of 15 contact hours (1.5 CEUs) of ACPE-accredited continuing pharmacy education credit accepted by the Oklahoma Board of Pharmacy and most other states. Credit will be earned based on the participation in individually accredited activities. Full attendance and participation are required before obtaining CPE credit. Partial credit will not be awarded. Any individual who is over 10 minutes late or leaves early will not be granted credit. The University of Oklahoma College of Pharmacy, as an ACPE-accredited provider, is required to report all credit through CPE Monitor. Credit will be available online to participants within four weeks. A notification email will be sent to participants when credit is uploaded. It is your responsibility to confirm that your credit has been uploaded correctly by 12/17/23. You must notify Cassidy Roberts of any errors or corrections before this date, as ACPE guidelines prohibit providers from issuing or modifying credit more than 60 days after the activity for any reason. The initial release date is 10/28/23. For successful completion and subsequent awarding of credit, the attendance verification procedure will require each participant to: sign in on the morning and afternoon sign-in sheet, provide NABP e-Profile ID # and month and day of birth, participate in the learning assessments, return nametag at the end of the final session attended, and complete the online program evaluation.

## **Commercial Support**

Commercial support is financial, or in-kind contribution given by an ineligible company, which is used to pay all or part of the costs of a CPE activity. No commercial support was received for this program.

## **Financial Disclosure and Mitigation Report**

The University of Oklahoma College of Pharmacy endorses the ACPE Standards for Integrity and Independence in Accredited Continuing Education. All accredited activities must be balanced, objective, independent of commercial bias and must promote improvements or quality in healthcare. All recommendations must be based on evidence accepted within the medical profession. We require that everyone in a position to control the content of an accredited educational activity disclose all financial relationships with ineligible companies of any amount within the last 24 months. The University of Oklahoma College of Pharmacy will identify, review and mitigate all relevant financial relationships that anyone in control of content disclose prior to an educational activity being delivered to learners. This policy is designed to provide the target audience with an opportunity to review any affiliations for the purpose of determining the potential presence of bias or influence over educational content.

The following individuals have disclosed a relevant financial relationship(s) with an ineligible company(ies). All of the relevant financial relationships listed below have been mitigated prior to the program. Paul Boylan (faculty) is a researcher for Pfizer. Kelly Murray (faculty) was a consultant for McGraw Hill and currently receives royalties from a book publication through McGraw Hill. Her consultant role has ended. She has attested that her presentation will not include discussion of products or services from the above listed ineligible company. Grant Skrepnek (faculty) has received research awards on behalf of the OU Health Sciences Center from Janssen, Pfizer, and Otsuka. All three financial relationships have ended. He has attested that his presentation will not include discussion of products or services from the above listed ineligible companies. All of the individuals have agreed to only present peer-reviewed,

published data and recommendations that have been approved, adhere to balanced and objective evidence-based guidelines, and attest that any recommendations are evidence-based and free of commercial bias. Additionally, all agreed to teach to the competencies identified by the learning objectives and present the source and type or level of evidence to participants. All presentation slides were reviewed for content validation and bias by the University of Oklahoma College of Pharmacy Office of Continuing Education.

None of the faculty or planning committee members listed below have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Kristie Edelen	Jordan Fuller	Jeremy Johnson	Cassidy Roberts
Marjan Fardadfar	Wendy Galbraith	Julia McElyea	Keith Swanson

### **Contact Information**

For any questions, concerns or grievances associated with this activity, please contact the OUCOP Continuing Education Administrator at (405) 271-6194 / Cassidy-Roberts@ouhsc.edu.

### **Registration and Refund Policies**

Pre-registration is suggested to allow OUCOP to provide the appropriate faculty and materials necessary to meet the program objectives. Early registration is \$150/day and will be accepted until 10/27/23. This includes all program materials, continental breakfast, lunch and refreshments. A link to the activity materials will be provided online for registered participants to download and/or print. OUCOP reserves the right to limit registrations or cancel courses and refund registration fees. There are no refunds in any other circumstance.

### **Equal Opportunity, Privacy, Confidentiality and Copyright Policies**

The University of Oklahoma is an equal opportunity institution. Accommodations on the basis of disability are available by contacting Cassidy-Roberts@ouhsc.edu. We are committed to protecting the privacy of our learners. Your personal information will not be shared with anyone outside of the Office of Continuing Education unless you consented to having your name and practice site shared with vendor representatives, if applicable. In that case, no contact details or any other information will be given out. Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of the University of Oklahoma or is licensed or has been granted permission for use by the copyright owner. No materials may be reproduced or transmitted without written permission. All rights reserved. To access the entirety of these policies, visit <https://ou.edu/marcomm/web-policies/termsfuse> and <https://ou.edu/eoo/about/policies-procedures>.